Recent studies have identified a high frequency of recurrent acquired DNA copy number abnormalities in pediatric ALL, most commonly involving genes regulating lymphoid development (
Disclosure:Research Funding: 1. Roche-sponsored gene expression profiling research unrelated to the current studies. 2. St. Jude co-owns a pending patent application with the University of Mississippi (Pub. No. 2004/0018513) drawn to leukemia gene expression profiling which has been nonexclusively licensed to Affymetrix. Membership Information: Board of Scientific Consultants for the Memorial Sloan-Kettering Cancer Center (J.R.D.). C.G.M. spoke at an Affymetrix symposium in 2007.